

Secretary, HHS, summarizing the results of completed dose reconstruction reviews.

The agenda is subject to change as priorities dictate.

**CONTACT PERSON FOR MORE INFORMATION:** Theodore Katz, Designated Federal Officer, NIOSH, CDC, 1600 Clifton Road, Mailstop E-20, Atlanta GA 30333, Telephone (513)533-6800, Toll Free 1(800) CDC-INFO, Email [ocas@cdc.gov](mailto:ocas@cdc.gov).

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2015-13311 Filed 6-1-15; 8:45 am]

**BILLING CODE 4163-19-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Centers for Disease Control and Prevention

#### Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review

In accordance with section 10(a)(2) of the Federal Advisory Committee Act (Pub. L. 92-463), the Centers for Disease Control and Prevention (CDC) announces a meeting for the initial review of applications in response to Funding Opportunity Announcement (FOA), IP-11-00100501PPHF15, PPHF-2015-Enhanced Surveillance for New Vaccine Preventable Disease—A Program Expansion for Acute Respiratory Illness Surveillance Financed Solely by 2015 Prevention and Public Health Funds.

*Time and Date:* 10:00 a.m.–3:00 p.m., June 23, 2015 (Closed).

*Place:* Teleconference.

*Status:* The meeting will be closed to the public in accordance with provisions set forth in section 552(b)(4) and (6), Title 5 U.S.C., and the Determination of the Director, Management Analysis and Services Office, CDC, pursuant to Public Law 92-463.

*Matters for Discussion:* The meeting will include the initial review, discussion, and evaluation of applications received in response to “PPHF-2015-Enhanced Surveillance for New Vaccine Preventable Disease—A

Program Expansion for Acute Respiratory Illness Surveillance Financed Solely by 2015 Prevention and Public Health Funds”, IP-11-00100501PPHF15.

*Contact Person for More Information:* Gregory Anderson, M.S., M.P.H., Scientific Review Officer, CDC, 1600 Clifton Road NE., Mailstop E60, Atlanta, Georgia 30333, Telephone: (404) 718-8833.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

**Elaine L. Baker,**

*Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.*

[FR Doc. 2015-13315 Filed 6-1-15; 8:45 am]

**BILLING CODE 4163-18-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Administration for Children and Families

[CFDA Number: 93.598]

#### Announcement of the Award of a Single-Source Program Expansion Supplement Grant to the U.S. Committee for Refugees and Immigrants in Arlington, VA

**AGENCY:** Office of Refugee Resettlement, ACF, HHS.

**ACTION:** Announcement of the award of a single-source program expansion supplement to the U.S. Committee for Refugees and Immigrants (USCRI) to support expanded services to foreign trafficking victims, potential trafficking victims, and certain family members.

**SUMMARY:** The Administration for Children and Families (ACF), Office of Refugee Resettlement (ORR) announces the award of a single-source program expansion supplement grant to U.S. Committee for Refugees and Immigrants in Arlington, Virginia for a total of \$1,060,805.

The supplemental funding will ensure that clients' essential needs, such as housing, transportation, communication, food, and medical care, will be met. The supplemental funding will also ensure that USCRI has sufficient staff for the increased number of cases.

**DATES:** The period of support under these supplements is June 01, 2015 through September 29, 2015.

**FOR FURTHER INFORMATION CONTACT:** Maggie Wynne, Director, Division of Anti-Trafficking in Persons, Office of Refugee Resettlement, 901 D Street SW., Washington, DC 20024, Telephone (202) 401-4664. Email: [maggie.wynne@acf.hhs.gov](mailto:maggie.wynne@acf.hhs.gov).

**SUPPLEMENTARY INFORMATION:** The National Human Trafficking Victim Assistance Program (NHTVAP) provides funding for comprehensive case management services to victims of trafficking and certain family members on a per capita basis. The NHTVAP grantees help clients gain access to housing, employability services, mental health screening and therapy, medical care, and some legal services. During FY 2015, a grantee, U.S. Committee for Refugees and Immigrants (USCRI), served more clients than it had planned for in its budget for the year. Without the additional funding, USCRI would have to make significant cuts in services to current clients and limit the enrollment of new clients. Also, without additional funding USCRI would not have sufficient programmatic support for the increase in client enrollments. With the supplemental funding, USCRI will be able to ensure that all of the clients' essential needs will be met.

**Statutory Authority:** Trafficking Victims Protection Act of 2000 (TVPA), as amended, Section 107(b)(1)(B), 22 U.S.C. 7105(b)(1)(B), authorizes funding for benefits and services to foreign victims of severe forms of trafficking in persons in the United States, potential victims of trafficking seeking HHS Certification, and certain family members.

**Christopher Beach,**

*Senior Grants Policy Specialist, Office of Administration.*

[FR Doc. 2015-13177 Filed 6-1-15; 8:45 am]

**BILLING CODE 4184-47-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2011-N-0279]

#### Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Prescription Drug Marketing Act of 1987; Policies, Requirements, and Administrative Procedures

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing